The therapeutic efficacy of thymidylate synthase on pemetrexed treatment of lung adenocarcinoma

Objective To investigate thymidylate synthase on pemetrexed treatment of lung adenocarcinoma effect relationship. Methods The 60 patients with lung adenocarcinoma in our hospital from January 2014 to January 2016 were selected as the research subjects. They were treated with pemetrexed. According to the clinical efficacy, they were divided into the effective group (n=27) and ineffective group (n=33) after 3 courses of treatment. The levels of thymidylate synthase (thymidylate synthase, TS), TS mRNA expression, and the expression of TS protein in the tumor tissues of two groups were analyzed by enzyme-linked immunoadsorbent assay (ELISA), fluorescence quantitative polymerase chain reaction (PCR), and immunohistochemistry. The relationship between TS level and pemetrexed in the treatment of lung adenocarcinoma was investigated. Results The level of ST in peripheral blood of the effective group was significantly lower than ineffective group. The objective response rate and protein of ST gene low expression were significantly higher than high expression of ST. Conclusions The level of thymidylate synthase in patients with adenocarcinoma of the lung is related to the therapeutic effect of pemetrexed in the treatment of adenocarcinoma of the lung. It can be used as a molecular marker to evaluate the clinical efficacy of pemetrexed in the treatment of patients with lung adenocarcinoma. Key words: Thymidylate synthase/ME; Taxoids/TU; Lung neoplasms/DT/ME